That kind of money makes the $10 billion it invested in OpenAI, back in 2023, seem like chump change. It's equivalent to ...
With a primary degree in computer science and software engineering from Maynooth University and an MSc in artificial ...
As the crypto industry is booming, 2025 is considered as the year for AI-based altcoins. Among the rising stars, Ozak AI (OZ) ...
Nvidia took the main keynote stage of CES 2025 to reveal its next generation of PC gaming and content creation graphics ...
After nearly a decade of machine learning innovations, the FDA has issued its first draft guidance on the use of AI in drug ...
The artificial intelligence (AI) boom has taken the stock market by storm. The S&P 500 ( ^GSPC 0.55%) has advanced 55% in the ...
AI doesn't need an introduction on the transformative changes it has brought across numerous industries. AI in product ...
Femto Technologies Inc. (Nasdaq: BCAN) ("Femto" or the "Company"), a Femtech pioneer and the creator of Sensera, a feminine ...
By deploying advanced artificial intelligence and machine learning capabilities, IPTA assists the DOD in accelerating the approval of new requirements, identifying and eliminating outdated plans, and ...
AI is a long way off from becoming Skynet, but it has its own set of risks and pitfalls, and we should stop using it.
The potential of using artificial intelligence in drug discovery and development has sparked both excitement and skepticism among scientists, investors and the general public.
Unlike AI, humans are shaped by diverse needs: navigating a 3D world, socializing, avoiding conflict, fighting when necessary ...